Targeted OncologyExpert Discusses Ongoing Immunotherapy Research in CRCTargeted OncologyThey are very responsive to immunotherapies. In fact, we have seen FDA approvals of pembrolizumab for patients with MSI-H cancers, as well as nivolumab for MSI-H … Continue reading
R & D Magazine |
What’s Next For CAR T: The Potential of Engineering Immune Cells to Treat Cancer
R & D Magazine CAR T-cell therapy is created by collecting a patient’s T-cells, genetically modifying them to fight cancer, and then infusing them back into the patient. The first therapy in this class, tisagenlecleucel (Kymriah), was FDA approved in August 2017 in … Researchers Build a Cancer Immunotherapy Without Immune CellsThe Scientist |
OncLive |
Questions Remain With CAR–T’s, Checkpoints in Hematologic Malignancies
OncLive Despite major progress with chimeric antigen receptor (CAR) T-cell therapy and immune checkpoint inhibitors in hematologic malignancies, questions remain regarding the use of these therapies in this landscape, according to Leo I. Gordon, MD. |
William & Mary News |
William & Mary team wins First Runner-Up position in iGEM competition
William & Mary News Each year iGEM hosts the largest synthetic–biology competition in the world, a months-long, student-driven projects involving biology, mathematics, chemistry and engineering. William & Mary’s team also won two special awards, one for Best Innovation in … |